G1A Stock Analysis: GEA | XETRA
Specialty Industrial Machinery | XETRA, Germany | Market Cap: 10.818m EUR | 12M Return: 9.5% | DE0006602006 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.1M
EPS Trend: 49.7%
Qual. Beats: 0
Rev. Trend: 84.7%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
GEA Group Aktiengesellschaft (XETRA: G1A) is a German industrial machinery supplier headquartered in Düsseldorf, founded in 1881 and renamed from mg technologies ag to its current form in 2005. The company designs and manufactures process-related components and machinery - including separators, decanters, homogenizers, valves, and pumps - for the food, beverage, and pharmaceutical industries worldwide. It operates through five reporting segments: Separation & Flow Technologies, Liquid & Power Technologies, Food & Health Technologies, Farm Technologies, and Heating & Refrigeration Technologies.
Beyond individual components, GEA delivers integrated process solutions spanning brewing, liquid processing and filling, concentration, fermentation, crystallization, purification, drying, powder handling, and packaging. It also supplies systems for carbon capture and emission control, as well as processing and packaging lines for meat, poultry, seafood, vegan, snack, and pasta products, plus pharmaceutical equipment such as freeze dryers, granulators, and tablet presses.
In its Farm Technologies segment, the company provides milking and feeding systems, manure handling, and digital herd management tools for dairy and livestock operations, while its Heating & Refrigeration Technologies segment serves industrial refrigeration and heating needs across food, beverage, dairy, and oil and gas end markets. As a large-cap industrial machinery group, GEAs revenue is closely tied to capital expenditure cycles in food and dairy processing, and it benefits from long-running structural trends in food processing automation, protein diversification, and pharmaceutical manufacturing capacity expansion.
- Dairy processing equipment demand lifts Separation segment orders
- Pharma capex growth accelerates Food & Health Technologies revenue
- Margin recovery hinges on pricing actions and cost program execution
| Net Income: 434.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.17 > 1.0 |
| NWC/Revenue: 2.88% < 20% (prev 1.05%; Δ 1.83% < -1%) |
| CFO/TA 0.12 > 3% & CFO 723.1m > Net Income 434.1m |
| Net Debt (240.5m) to EBITDA (913.0m): 0.26 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (162.8m) vs 12m ago 0.0% < -2% |
| Gross Margin: 37.50% > 18% (prev 36.82%; Δ 0.67% > 0.5%) |
| Asset Turnover: 96.40% > 50% (prev 96.50%; Δ -0.10% > 0%) |
| Interest Coverage Ratio: 14.83 > 6 (EBIT TTM 680.7m / Interest Expense TTM 45.9m) |
| A: 0.03 (Total Current Assets 2.72b - Total Current Liabilities 2.56b) / Total Assets 6.08b |
| B: 0.13 (Retained Earnings 792.9m / Total Assets 6.08b) |
| C: 0.12 (EBIT TTM 680.7m / Avg Total Assets 5.85b) |
| D: 0.70 (Book Value of Equity 2.50b / Total Liabilities 3.58b) |
| Altman-Z'' = 2.12 = BBB |
| DSRI: 1.17 (Receivables 1.27b/1.04b, Revenue 5.64b/5.43b) |
| GMI: 0.98 (GM 36.82% / 37.50%) |
| AQI: 0.96 (AQ_t 0.39 / AQ_t-1 0.40) |
| SGI: 1.04 (Revenue 5.64b / 5.43b) |
| TATA: -0.05 (NI 434.1m - CFO 723.1m) / TA 6.08b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of October 09, 2026, the stock is trading at EUR 67.35 with a total of 283,135 shares traded. Over the past week, the price has changed by +2.36%, over one month by +3.62%, over three months by +12.91% and over the past year by +9.48%.
Current recommended Stop Loss: 65.80 (which is 2.3% or 1.3 ATR below the current price).
GEA has no consensus analysts rating.
P/E Trailing = 24.7948
P/E Forward = 16.5563
P/S = 1.9187
P/B = 4.326
P/EG = 0.9948
Revenue TTM = 5.64b EUR
EBIT TTM = 680.7m EUR
EBITDA TTM = 913.0m EUR
Long Term Debt = 143k EUR (from longTermDebt, last fiscal year)
Short Term Debt = 122.7m EUR (from shortTermDebt, last quarter)
Debt = 573.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 246.4m
Net Debt = 240.5m EUR (calculated: Debt 573.6m - CCE 333.2m)
Enterprise Value = 11.1b EUR (10.8b + Debt 573.6m - CCE 333.2m)
Interest Coverage Ratio = 14.83 (Ebit TTM 680.7m / Interest Expense TTM 45.9m)
EV/FCF = 22.71x (Enterprise Value 11.1b / FCF TTM 487.0m)
FCF Yield = 4.40% (FCF TTM 487.0m / Enterprise Value 11.1b)
FCF Margin = 8.63% (FCF TTM 487.0m / Revenue TTM 5.64b)
Net Margin = 7.70% (Net Income TTM 434.1m / Revenue TTM 5.64b)
Gross Margin = 37.50% ((Revenue TTM 5.64b - Cost of Revenue TTM 3.53b) / Revenue TTM)
Gross Margin QoQ = 38.64% (prev 38.06%)
Tobins Q-Ratio = 1.82 (Enterprise Value 11.1b / Total Assets 6.08b)
Interest Expense / Debt = 8.00% (Interest Expense 45.9m / Debt 573.6m)
Taxrate = 31.30% (199.1m / 636.0m)
NOPAT = 467.6m (EBIT 680.7m * (1 - 31.30%))
Current Ratio = 1.06 (Total Current Assets 2.72b / Total Current Liabilities 2.56b)
Debt / Equity = 0.23 (Debt 573.6m / totalStockholderEquity, last quarter 2.50b)
Debt / EBITDA = 0.26 (Net Debt 240.5m / EBITDA 913.0m)
Debt / FCF = 0.49 (Net Debt 240.5m / FCF TTM 487.0m)
Total Stockholder Equity = 2.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.42% (Net Income 434.1m / Total Assets 6.08b)
RoE = 17.54% (Net Income TTM 434.1m / Total Stockholder Equity 2.48b)
RoCE = 27.50% (EBIT 680.7m / Capital Employed (Equity 2.48b + L.T.Debt 143k))
RoIC = 13.93% (NOPAT 467.6m / Invested Capital 3.36b)
WACC = 6.64% (E(10.8b)/V(11.4b) * Re(6.70%) + D(573.6m)/V(11.4b) * Rd(8.00%) * (1-Tc(0.31)))
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -89.99 | Cagr: -1.88%
[DCF] Terminal Value 76.71% ; FCFF base≈468.7m ; Y1≈511.1m ; Y5≈638.4m
[DCF] Fair Price = 58.51 (EV 9.77b - Net Debt 240.5m = Equity 9.53b / Shares 162.8m; r=8.35% [WACC [floored]]; 5y FCF grow 10.40% → 2.50% )
EPS Correlation: 49.66 | EPS CAGR: 1.91% | SUE: -0.58 | # QB: 0
Revenue Correlation: 84.75 | Revenue CAGR: 1.58% | SUE: 1.53 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.09 | Chg30d=+1.39% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=3.37 | Chg30d=-0.63% | Revisions=+69% | GrowthEPS=+22.8% | GrowthRev=+6.9%
EPS next Year (2027-12-31): EPS=3.74 | Chg30d=-0.62% | Revisions=+57% | GrowthEPS=+11.1% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: +76% (up=17, down=1)